Home  |  NTCC Priorities

NTCC Priorities

• 1. Increase consumer demand for evidence-based tobacco cessation treatments and services
• 2. Link tobacco control public policy changes to increase cessation and treatment use and demand
• 3. Promote the inclusion and use of tobacco control and cessation content in electronic health records (EHRs)
• 4. Increase national, state and local longitudinal surveillance of tobacco-use cessation, including quitting motivation and behaviors, treatment beliefs and use, services, and policies
• 5. Expand access to proven, effective treatments for tobacco addiction
• 6. Support an expanded research agenda to achieve advances in the reach, effectiveness and adoption of tobacco cessation interventions across both individuals and populations
• 7. Launch an ongoing, extensive, national paid media campaign on cessation to help Americans quit using tobacco
• 8. Support the increase in the federal and state excise tax on tobacco to expand assistance for tobacco users who want to quit
• 9. Build capacity for quitlines in order to provide universal access to evidence-based counseling and medications for tobacco cessation

National Priority #6

Support an expanded research agenda to achieve advances in the reach, effectiveness and adoption of tobacco cessation interventions across both individuals and populations

Both the PHS Clinical Practice Guideline and the Guide to Community Preventive Services identified many future research questions pertaining to successful treatment of tobacco dependence that, if answered, could dramatically improve cessation rates and reduce health disparities due to tobacco use. The PHS Clinical Practice Guideline suggests that research should focus on the development of effective interventions and delivery strategies for populations that carry a disproportionate burden from tobacco (e.g., adolescents; pregnant smokers; American Indians and Alaska Natives; individuals with low SES/limited educational attainment; individuals with psychiatric disorders, including substance use disorders).

Featured Partner Activity

NTCC partner National Institute on Drug Abuse (NIDA) is focused on research in a variety of topic areas to advances in the reach, effectiveness and adoption of tobacco cessation interventions across both individuals and populations. Current NIDA areas of interest include pharmacogenetics, genes/environment interactions, and behavioral and integrative treatment development.

In addition to their existing research agenda, NIDA has received additional funding as part of the American Recovery and Reinvestment Act (ARRA) of 2009. ARRA provided NIDA with $10.4 B for 2 years, including $8.2 B in support of scientific research priorities, $300 M shared instrumentation and equipment, and $400 M Comparative Effectiveness Research. These include:

• Challenge Grants provide RC1 $200M using RC1 mechanism. Topics include behavior, behavioral change, and prevention; biomarker discovery and validation; clinical research, comparative effectiveness research (CER); genomics; health disparities; information technology for processing health care data; and translational science. http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-003.html
• Research and Research Infrastructure "Grand Opportunities" (aka GO Grants) provide $200M using RC2 mechanism. This supports high impact ideas that lend themselves to short-term funding, and may lay the foundation for new fields of investigation. Topics include: vaccines and immunotherapies, brain development and genetics, biomarkers and phenotypes and environment. http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-004.html
• Biomedical Research Core Centers to Enhance Research Resources allocates $100 M using P30 mechanism to provide institutional awards for support of shared resources. http://grants.nih.gov/grants/guide/rfa-files/RFA-OD-09-005.html

Other Partner Activities

NTCC partners are currently conducting many activities related to this priority. For a list of these NTCC partner activities, click here.